Stockreport

AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF I maintain a "Hold" rating on both ANAB and TRAX, given the need for further clinical data and clarity on pipeline advancement and partnerships. ANAB retains royalty [Read more]